The p53-deficient mouse: A model for basic and applied cancer studies

Seminars in Cancer Biology

Volumn 7, Issue 5, 1996, Pages 269-278

  Donehower, Lawrence A ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Gene targeting; Knockout; Li Fraumeni syndrome; Mouse; p53; Tumor model; Tumor suppressor

Indexed keywords

PROTEIN P53;

ANIMAL MODEL; CANCER MODEL; CANCER PREVENTION; CANCER RESEARCH; CANCER SUSCEPTIBILITY; CARCINOGENESIS; FAMILIAL CANCER; GENE TARGETING; MOUSE; MOUSE MUTANT; NONHUMAN; REVIEW; TUMOR GROWTH; TUMOR SUPPRESSOR GENE;

EID: 0030265337     PISSN: 1044579X     EISSN: None     Source Type: Journal    
DOI: 10.1006/scbi.1996.0035     Document Type: Review

References (73)

1. 1. Capecchi MR (1989) Altering the genome by homologous recombination. Science 244:1288-1292
2. 2. Frohman MA, Martin GR (1989) Cut, paste, and save: new approaches to altering specific genes in mice. Cell 56:145-147
3. 3. Greenblatt MS, Bennett W, Hollstein M, Harris CC (1994) Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res 54:4855-4878
4. 4. Donehower LA, Harvey M, Slagle BL, McArthur MJ, Montgomery CA Jr, Butel JS, Bradley A (1992) Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature 356:215-221
5. 5. Finlay CA, Hinds PW, Levine AJ (1989) The p53 protooncogene can act as a suppressor of transformation. Cell 57:1083-1093
6. 6. Eliyahu D, Michalovitz D, Eliyahu S, Pinhasi-Kimhi O, Oren M (1989) Wild-type p53 can inhibit oncogene-mediated focus formation. Proc Natl Acad Sci USA 86:8763-8767
7. 7. Hinds P, Finlay C, Levine AJ (1989) Mutation is required to activate the p53 gene for cooperation with the ras oncogene and transformation. J Virol 63:739-746
8. 8. Milner J, Medcalf EA (1991) Cotranslation of activated mutant p53 with wild type drives the wild-type p53 protein into the mutant conformation. Cell 65:765-774
9. 9. Kuerbitz SJ, Plunkett BS, Walsh WV, Kastan MB (1992) Wild-type p53 is a cell cycle checkpoint determinant following irradiation. Proc Natl Acad Sci USA 89:7491-7495
10. 10. Kastan MB, Zhan Q, El-Deiry WS, Carrier F, Jacks T, Walsh WV, Plunkett BS, Vogelstein B, Fornace AJ Jr (1992) A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia telangiectasia. Cell 71:587-597
11. 11. Yonish-Rouach, Resnitzky D, Lotem J, Sachs L, Kimchi A, Oren M (1991) Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6. Nature 352:345-347
12. 12. Lane DP (1992) p53, guardian of the genome. Nature 358:15-16
13. 13. Malkin D, Li FP, Strong LC, Fraumeni JF, Nelson CE, Kim DH, Kassell J, Gryka MA, Bischoff FZ, Tainsky MA, Friend SH (1990) Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science 250:1233-1238
14. 14. Srivastava S, Zou Z, Pirollo K, Blattner W, Chang EH (1990) Germ-line transmission of a mutated p53 gene in a cancer-prone family with Li-Fraumeni syndrome. Nature 348:747-749
15. 15. Jacks T, Remington L, Williams BO, Schmitt EM, Halachmi S, Bronson RT, Weinberg RA (1994) Tumor spectrum analysis in p53-mutant mice. Curr Biol 4:1-7
16. 16. Purdie CA, Harrison DJ, Peter A, Dobbie L, White S, Howie SEM, Salter DM, Bird CC, Wyllie AH, Hooper ML, Clarke AR (1994) Tumour incidence, spectrum and ploidyin mice with a large deletion in the p53 gene. Oncogene 9:603-609
17. 17. Tsukada T, Tomooka Y, Takai S, Ueda Y, Nishikawa S, Yagi T, Tokunaga T, Takeda N, Suda Y, Abe S, Matsuo I, Ikawa Y, Aizawa S (1993) Enhanced proliferative potential in culture of cells from p53-deficient mice. Oncogene 8:3313-3322
18. 18. Gondo Y, Nakamura K, Nakao K, Sasaoka T, Ito K, Kimura M, Katsuki M (1994) Gene replacement of the p53 gene with the lacZ gene in mouse embryonic stem cells and mice by using two steps of homologous recombination. Biochem Biophys Res Commun 202:830-837
19. 19. Sah VP, Attardi LD, Mulligan GJ, Williams BO, Bronson RT, Jacks T (1995) A subset of p53-deficient embryos exhibit exencephaly. Nature Genet 10:175-180
20. 20. Armstrong JF, Kaufman MH, Harrison DJ, Clarke AR (1995) High-frequency developmental abnormalities in p53-deficient mice. Curr Biol 5:931-936
21. 21. Harvey M, McArthur MJ, Montgomery CA, Butel JS, Bradley A, Donehower LA (1993) Spontaneous and carcinogen-induced tumorigenesis in p53-deficient mice. Nature Genet 5:225-229
22. 22. Donehower LA, Harvey M, Vogel H, McArthur MJ, Montgomery CA Jr, Park SH, Thompson T, Ford RJ, Bradley A (1995) Effects of genetic background on tumorigenesis in p53-deficient mice. Mol Carcinogen 14:16-22
23. 23. Harvey M, McArthur MJ, Montgomery CA, Bradley A, Donehower LA (1993) Genetic background alters the spectrum of tumors that develop in p53-deficient mice. FASEB J 7:938-943
24. 24. Stevens LC, Little CC (1954) Spontaneous testicular teratomas in an inbred strain of mice. Proc Natl Acad Sci USA 40:1080-1087
25. 25. Toguchida J, Tamaguchi T, Dayton SH, Beauchamp RL, Herrera GE, Ishizaki K, Yamamuro T, Meyers PA, Little JB, Sasaki MS, Weichselbaum RR, Yandell DW (1992) Prevalence and spectrum of germline mutations of the p53 gene among patients with sarcoma. NEJM 326:1301-1308
26. 26. Frebourg T, Barbier N, Yan Y-X, Garber JE, Dreyfus M, Fraumeni J Jr, Li FP, Friend SH (1995) Germ-line p53 mutations in 5 families with Li-Fraumeni syndrome. Am J Hum Genet 56:608-615
27. 27. Lavigueur A, Maltby V, Mock D, Rossant J, Pawson T, Bernstein A (1989) High incidence of lung, bone, and lymphoid tumors in transgenic mice overexpressing mutant alleles of the p53 oncogene. Mol Cell Biol 9:3982-3991
28. 28. Harvey M, Vogel H, Morris D, Bradley A, Bernstein A, Donehower LA (1995) A mutant p53 transgene accelerates tumour development in heterozygous but not nullizygous p53-deficient mice. Nature Genet 9:305-311
29. 29. Jones SN, Roe AE, Donehower LA, Bradley A (1995) Embryonic lethality in Mdm2-deficient mice by absence of p53. Nature 378:206-208
30. 30. Montes de Oca Luna R, Wagner DS, Lozano G (1995) Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53. Nature 378:203-206
31. 31. Knudson AG (1971) Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci USA 68:820-823
32. 32. Cavenee WK, Hansen MF, Nordenskjold M, Kock E, Maumenee I, Squire JA, Phillips RA, Gallie BL (1985) Genetic origin of mutations predisposing to retinoblastoma. Science 228:501-503
33. 33. Jacks T, Fazeli A, Schmitt EM, Bronson RT, Doodell MA, Weinberg RA (1992) Effects of an Rb mutation in the mouse. Nature 359:295-300
34. 34. Hu N, Gutsmann A, Herbert DC, Bradley A, Lee WH, Lee EYHP (1994) Heterozygous Rb-1 delta 20/ + mice are predisposed to tumors of the pituitary gland with nearly completed penetrance. Oncogene 9:1021-1027
35. 35. Kemp CJ, Donehower LA, Bradley A, Balmain A (1993) Reduction of p53 gene dosage does not increase initiation or promotion but enhances malignant progression of chemically induced skin tumors. Cell 74:813-822
36. 36. Ziegler A, Jonason AS, Leffell DJ, Simon JA, Sharma HW, Kimmelman J, Remington L, Jacks T, Brash DE (1994) Sunburn and p53 in the onset of skin cancer. Nature 372:773-776
37. 37. Pan HC, Griep AE (1994) Altered cell cycle regulation in the lens of HPV-16 E6 or E7 transgenic mice - implications for tumor suppressor gene function in development. Genes Dev 8:1285-1299
38. 38. Howes KA, Ransom N, Papermaster DS, Lasudry JGH, Albert DM, Windle JJ (1994) Apoptosis or retinoblastoma - alternative fates of photoreceptors expressing the HPV-16 E7 gene in the presence or absence of p53 Genes Dev 8:1300-1310
39. 39. Symonds H, Krail L, Remington L, Saenz-Robles M, Lowe S, Jacks T, Van Dyke T (1994) p53-dependent apoptosis suppresses tumor growth and progression in vivo. Cell 78:703-711
40. 40. Donehower LA, Godley LA, Aldaz CM, Pyle R, Shi Y-P, Pinkel D, Gray J, Bradley A, Medina D, Varmus HE (1995) Deficiency of p53 accelerates mammary tumorigenesis in Wnt-1 transgenic mice and promotes chromosomal instability. Genes Dev 9:882-895
41. 41. Tsukamoto AS, Grosschedl R, Guman RC, Parslow T, Varmus HE (1988) Expression of the int-1 gene in transgenic mice is associated with mammary gland hyperplasia and adenocarcinomas in male and female mice. Cell 55:619-625
42. 42. Harvey M, Sands AT, Weiss RS, Hegi ME, Wiseman RW, Pantazis P, Giovanella BC, Tainsky MA, Bradley A, Donehower LA (1993) In-vitro growth characteristics of embryo fibroblasts isolated from p53-deficient mice. Oncogene 8:2457-2467
43. 43. Rong S, Donehower LA, Hansen M, Strong L, Tainsky M, Jeffers M, Resau JH, Resau JH, Hudson E, Tsarfaty I, Vande Woude GF (1995) Met protooncogene product is overexpressed in tumors of p53-deficient mice and tumors of Li-Fraumeni patients. Cancer Res 55:1963-1970
44. 44. Livingstone LR, White A, Sprouse J, Livanos E, Jacks T, Tlsty TD (1992) Altered cell cycle arrest and gene amplification potential accompany loss of wild type p53. Cell 70:605-620
45. 45. Yin Y, Tainsky MA, Bischoff FZ, Strong LC, Wahl GM (1992) Wild type p53 restores cell cycle control and inhibits gene amplification in cells with mutant p53 alleles. Cell 70:937-948
46. 46. Stewart N, Hicks GG, Paraskevas F, Mowat M (1995) Evidence for a second cell cycle block at G2/ M by p53. Oncogene 10:109-115
47. 47. Agarwal ML, Agarwal A, Taylor WR, Stark GR (1995) p53 controls both the G2/ M and the G1 cell cycle checkpoints and mediates reversible growth arrest in human fibroblasts. Proc Natl Acad Sci USA 2:8493-8497
48. 48. Cross SM, Sanchez CA, Morgan CA, Schimke MK, Ramel S, Idzerda RL, Raskind WH, Reid BJ (1995) A p53-dependent mouse spindle checkpoint. Science 267:1353-1356
49. 49. Fukasawa K, Choi T, Kuriyama R, Rulong S, Vande Woude GF (1996) Abnormal centrosome amplification in the absence of p53. Science 271:1744-1747
50. 50. Clarke AR, Purdie CA, Harrison DJ, Morris RG, Bird CC, Hooper ML, Wyllie AH (1993) Thymocyte apoptosis induced by p53-dependent and independent pathways. Nature 362:849-852
51. 51. Lowe SW, Schmitt EM, Smith SW, Osborne BA, Jacks T (1993) p53 is required for radiation-induced apoptosis in mouse thymocytes. Nature 362:847-849
52. 52. Lowe SW, Jacks T, Housman DE, Ruley HE (1994) Abrogation of oncogene-associated apoptosis allows transformation of p53-deficient cells. Proc Natl Acad Sci USA 91:2026-2030
53. 53. Hermeking H, Eick D (1994) Mediation of c-Myc-induced apoptosis by p53. Science 265:2091-2093
54. 54. Graeber TG, Osmanian C, Jacks T, Housman DE, Koch CJ, Lowe SW, Giaccia AJ (1996) Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumors. Nature 379:88-91
55. 55. Yahanda A, Bruner J, Donehower LA, Morrison R (1995) p53-deficient neonatal astrocytes as an in vitro model for glioblastoma development. Mol Cell Biol 15:4249-4259
56. 56. Tennant RW, French JE, Spalding JW (1995) Identifying chemical carcinogens and assessing potential risk in short-term bioassays using transgenic mouse models. Environ Health Perspect 103:942-950
57. 57. Hursting S, Perkins SN, Phang JM (1994) Calorie restriction delays spontaneous tumorigenesis in p53-knockout transgenic mice. Proc Natl Acad Sci USA 91:7036-7040
58. 58. Hursting SD, Perkins SN, Haines DC, Ward JM, Phang JM (1995) Chemoprevention of spontaneous tumorigenesis in p53-Knockout mice. Cancer Res 55:3949-3953
59. 59. Nicol CJ, Harrison ML, Laposa RR, Gimelshtein IL, Wells PG (1995) A teratologic suppressor role for p53 in benzo[a]pyrene-treated transgenic p53-deficient mice. Nature Genet 10:181-187
60. 60. Norimura T, Nomoto S, Katsuki M, Gondo Y, Kondo S (1996) p53-dependent apoptosis suppresses radiation-induced teratogenesis. Nature Med 2:577-580
61. 61. Wubah JA, Ibrahim MM, Gao X, Nguyen D, Pisano MM, Knudsen TB (1996) Teratogen-induced eye defects mediated by p53-dependent apoptosis. Curr Biol 6:60-69
62. 62. Williams BO, Remington L, Albert DM, Mukai S, Bronson RT, Jacks T (1994) Cooperative tumorigenic effects of germline mutations in Rb and p53. Nature Genet 7:480-484
63. 63. Harvey M, Vogel H, Lee EYH-P, Bradley A, Donehower LA (1995) Mice deficient in both p53 and Rb develop tumors primarily of endocrine origin. Cancer Res 55:1146-1151
64. 64. Elson A, Deng C, Campos-Torres J, Donehower LA, Leder P (1995) The MMTV/ c-myc transgene and p53 null alleles collaborate to induce T-cell lymphomas, but not mammary carcinomas in transgenic mice. Oncogene 11:181-190
65. 65. Blyth K, Terry A, O'Hara M, Baxter EW, Campbell M, Stewart M, Donehower LA, Onions DE, Neil JC, Cameron ER (1995) Synergy between a human c-myc transgene and p53 null genotype in murine thymic lymphomas: early and late effects of p53 loss. Oncogene 10:1717-1723
66. 66. Marin MC, Hsu B, Meyn R, Donehower LA, El-Naggar AK, McDonnell TJ (1994) Evidence that p53 and bcl-2 are regulators of a common cell death pathway important for in vivo lymphomagenesis. Oncogene 9:3107-3112
67. 67. Guidos CJ, Williams CJ, Grandal I, Knowles G, Huang MTF, Danska JS (1996) V(D)J recombination activates a p53-dependent damage checkpoint in scid lymphocyte precursors. Genes Dev 10:2038-2054
68. 68. Nacht M, Strasser A, Chan YR, Harris AW, Schlissel M, Bronson RT, Jacks T (1996) Mutations in the p53 and SCID genes cooperate in tumorigenesis. Genes Dev 10:2055-2066
69. 69. Clarke AR, Cummings MC, Harrison DJ (1995) Interaction between murine germline mutations in p53 and APC predisposes to pancreatic neoplasia but not to increased intestinal malignancy. Oncogene 11:1913-1920
70. 70. Kemp CJ, Wheldon T, Balmain A (1994) p53-deficient mice are extremely susceptible to radiation-induced tumorigenesis. Nature Genet 8:66-69
71. 71. Kemp CJ (1995) Hepatocarcinogenesis in p53-deficient mice. Mol Carcinogen 12:132-136
72. 72. Jerry DJ, Butel JS, Donehower LA, Paulson EJ, Cochran C, Wiseman RW, Medina D (1994) Infrequent p53 mutations in 7,12-dimethylbenz[a]anthracene-induced mammary tumors in BALB/ c and p53 hemizygous mice. Mol Carcinogen 9:175-183
73. 73. Matzinger SA, Crist KA, Stoner GD, Anderson MW, Pereira MA, Steele VE, Kelloff GJ, Lubet RA, You M (1995) K-ras mutations in lung tumors from A/ J and A/ J X TSG-p53 F1 mice treated with 4-(methylnitrosamino)-1-(3-pyridyl)-l-butanone and phenethyl isothiocyanate. Carcinogenesis 16:2487-2492